Clinical Trial

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Protocol Amendment History 4 changes
notable Enrollment increased: 405 -> 572 participants 2026-07-28
minor Trial arms changed: 1 -> 2 2026-07-28
notable Primary completion moved earlier: 2029-05 -> 2028-03 2026-07-28
notable Trial sites expanded: 15 -> 20 locations 2026-06-05
Trial Details
NCT Number NCT07066657
Lead Sponsor ArriVent BioPharma, Inc.
Collaborators: Lepu Biopharma Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
Enrollment 572 participants
Start Date 2025-07-25
Primary Completion 2028-03 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13